<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        14-584-17
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2017
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        LEVANIX 500 mg film-coated tablet
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        LEVOFLOXACIN
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        500
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        7
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        56.55
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="NEOPHARMA" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            NEOPHARMA
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 540]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            ZIMMO TRADING ESTABLISHMENT
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            NEOPHARMA
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        J01MA12
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        S01AX19 
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The name of your medicine is LEVANIX. LEVANIX contains a medicine called levofloxacin. This<br />belongs to a group of medicines called antibiotics. Levofloxacin is a &lsquo;quinolone&rsquo; antibiotic. It<br />works by killing the bacteria that cause infections in your body.<br />LEVANIX can be used to treat infections of the:<br />&bull; Sinuses<br />&bull; Lungs, in people with long-term breathing problems or pneumonia<br />&bull; Urinary tract, including your kidneys or bladder<br />&bull; Prostate gland, where you have a long lasting infection<br />&bull; Skin and underneath the skin, including muscles. This is sometimes called &lsquo;soft tissue&rsquo;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>You are allergic to levofloxacin, any other quinolone antibiotic such as moxifloxacin,<br />ciprofloxacin or ofloxacin or any of the other ingredients of LEVANIX (listed in Section 6<br />below). Signs of an allergic reaction include: a rash, swallowing or breathing problems,<br />swelling of your lips, face, throat or tongue.<br />&bull; You have ever had epilepsy<br />&bull; You have ever had a problem with your tendons such as tendonitis that was related to<br />treatment with a &lsquo;quinolone antibiotic&#39;. A tendon is the cord that joins your muscle to your<br />skeleton<br />&bull; You are a child or a growing teenager<br />&bull; You are pregnant, might become pregnant or think you may be pregnant<br />&bull; You are breast-feeding<br />Do not take this medicine if any of the above applies to you. If you are not sure, talk to your<br />doctor or pharmacist before taking LEVANIX.<br />Take special care with LEVANIX<br />Check with your doctor or pharmacist before taking your medicine if:<br />&bull; You are 65 years of age or older<br />&bull; You are using corticosteroids, sometimes called steroids (see &ldquo;Taking other medicines&rdquo;<br />below)<br />&bull; You have ever had a fit (seizure)<br />&bull; You have had damage to your brain due to a stroke or other brain injury<br />&bull; You have kidney problems<br />&bull; You have something known as &lsquo;glucose &ndash; 6 &ndash; phosphate dehydrogenase deficiency&rsquo;. You<br />are more likely to have serious problems with your blood when taking this medicine<br />&bull; You have ever had mental health problems<br />&bull; You have ever had heart problems<br />&bull; You are diabetic<br />&bull; You have ever had liver problems<br />If you are not sure if any of the above applies to you, talk to your doctor or pharmacist before<br />taking LEVANIX.<br />Taking other medicines<br />Please tell your doctor or pharmacist if you are taking or have recently taken any other<br />medicines.<br />This includes medicines you buy without a prescription, including herbal medicines. This is<br />because LEVANIX can affect the way some other medicines work. Also some medicines can<br />affect the way LEVANIX works.<br />In particular, tell your doctor if you are taking any of the following medicines. This is<br />because it can increase the chance of you getting side effects, when taken with LEVANIX<br />tablets:<br />&bull; Corticosteroids, sometimes called steroids &ndash; used for inflammation. You may be more likely<br />to have inflammation and/or breakage of your tendons.<br />&bull; Warfarin - used to thin the blood. You may be more likely to have a bleed. Your doctor may<br />need to take regular blood tests to check how well your blood can clot.<br />&bull; Theophylline - used for breathing problems. You are more likely to have a fit (seizure) if<br />taken with LEVANIX.<br />&bull; Non-steroidal anti-inflammatory drugs (NSAIDS) used for pain and inflammation such as<br />aspirin, ibuprofen, fenbufen, ketoprofen and indomethacin. You are more likely to have a<br />fit (seizure) if taken with LEVANIX.<br />&bull; Ciclosporin - used after organ transplants. You may be more likely to get the side effects of<br />Ciclosporin<br />&bull; Medicines known to affect the way your heart beats. This includes medicines used for<br />abnormal heart rhythm (antiarrhythmics such as quinidine and amiodarone), for depression<br />(tricyclic antidepressants such as amitriptyline and imipramine) and for bacterial infections<br />(&lsquo;macrolide&rsquo; antibiotics such as erythromycin, azithromycin and Clarithromycin).<br />&bull; Probenecid - used for gout, and cimetidine - used for ulcers and heartburn. Special care<br />should be taken when taking either of these medicines with LEVANIX. If you have kidney<br />problems, your doctor may want to tgive you a lower dose.<br />Do not take LEVANIX at the same time as the following medicines. This is because it can<br />affect the way LEVANIX works:<br />&bull; Iron tablets (for anaemia), magnesium or aluminium-containing antacids (for acid or<br />heartburn) or sucralfate (for stomach ulcers). See Section 3 &ldquo;If you are already taking iron<br />tablets, antacids or sucralfate&rdquo; below.</p><p>Urine tests for opiates<br />Urine tests may show &lsquo;false-positive&rsquo; results for strong painkillers called &lsquo;opiates&rsquo; in people<br />taking LEVANIX. If your doctor is due to take a urine test, tell them you are taking LEVANIX.<br />Pregnancy and breast-feeding<br />Pregnancy Category C. Do not take this medicine if:<br />&bull; You are pregnant, might become pregnant or think you may be pregnant.<br />&bull; You are breast-feeding or planning to breast-feed<br />Ask your doctor or pharmacist for advice before taking any medicine if you are pregnant or<br />breast-feeding.<br />Driving and using machines<br />You may get side effects after taking this medicine, including feeling dizzy, sleepy, a spinning<br />feeling (vertigo) or changes to your eyesight. Some of these side effects can affect you being<br />able to concentrate and your reaction&nbsp;speed. If this happens, do not drive or carry out any work<br />that requires a high level of attention.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take LEVANIX exactly as your doctor has told you. You should check with your doctor<br />or pharmacist if you are not sure.<br />Taking this medicine<br />&bull; Take this medicine by mouth<br />&bull; Swallow the tablets whole with a drink of water<br />&bull; The tablets may be taken during meals or at any time between meals<br />Protect your skin from sunlight<br />Keep out of direct sunlight while taking this medicine. This is because your skin will become<br />much more sensitive to the sun and may burn, tingle or severely blister if you do not take the<br />following precautions:<br />&bull; Make sure you use high factor sun cream<br />&bull; Always wear a hat and clothes which cover your arms and legs<br />&bull; Avoid sun beds<br />If you are already taking iron tablets, antacids or sucralfate<br />&bull; Do not take these medicines at the same time as LEVANIX. Take your dose at least 2 hours<br />before or after LEVANIX.<br />How much to take<br />&bull; Your doctor will decide on how many LEVANIX you should take<br />&bull; The dose will depend on the type of infection you have and where the infection is in your body<br />&bull; The length of your treatment will depend on how serious your infection is<br />&bull; If you feel the effect of your medicine is too weak or strong, do not change the dose<br />yourself, but ask your doctor<br />Adults and the elderly<br />Sinusitis<br />One tablet of LEVANIX 500 mg, once each day<br />Lungs:<br />Pneumonia<br />One tablet of LEVANIX 500 mg, once or twice each day<br />In people with long-term breathing problems<br />1/2 tablet or one tablet of LEVANIX 500 mg, once each day&nbsp;Urinary tract, including your kidneys or bladder<br />1/2 tablet of LEVANIX 500 mg, each day<br />Prostate gland<br />One tablet of LEVANIX 500 mg, once each day<br />Skin and underneath the skin, including muscles<br />&frac12; tablet or one tablet of LEVANIX 500 mg, once or twice each day<br />Adults with kidney problems<br />Your doctor may need to give you a lower dose.<br />Children and Teenagers<br />This medicine must not be given to children or teenagers.<br />If you take more LEVANIX than you should<br />If you accidentally take more tablets than you should, tell a doctor or get other medical advice<br />straight away. Take the medicine pack with you so the doctor knows what you have taken. The<br />following effects may happen: Convulsive fits (seizures), feeling confused, dizzy, less conscious<br />and heart problems - leading to uneven heart beats as well as feeling sick (nausea).<br />If you forget to take LEVANIX<br />If you forgot to take a dose, take it as soon as you remember unless it is nearly time for your<br />next dose. Do not double-up the next dose to make up for the missed dose.<br />If you stop taking LEVANIX<br />Do not stop taking LEVANIX just because you feel better. It is important that you complete the<br />course of tablets that your doctor has prescribed for you. If you stop taking the tablets too soon,<br />the infection may return, your condition may get worse or the bacteria may become resistant to<br />the medicine.<br />If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, LEVANIX can cause side effects, although not everybody gets them. These<br />effects are normally mild or moderate and often disappear after a short time.<br />Stop taking LEVANIX and see a doctor or go to a hospital straight away if you notice the<br />following side effect:<br />Very rare (affects less than 1 person in 10,000) You have an allergic reaction. The signs may<br />include: a rash, swallowing or breathing problems, swelling of your lips, face, throat, or tongue.<br />Stop taking LEVANIX and see a doctor straight away if you notice any of the following<br />serious side effects &ndash; you may need urgent medical treatment:<br />Rare (affects less than 1 person in 1000) - Watery diarrhoea which may have blood in it,<br />possibly with stomach cramps and a high temperature. These could be signs of a severe bowel<br />problem; Pain and inflammation in your tendons. The Achilles tendon is affected most often and<br />in some cases, the tendon could break; Fits (convulsions);Very rare (affects less than 1 person<br />in 10,000) - Burning, tingling, pain or numbness. These may be signs of a disorder called<br />neuropathy; Other: - Severe skin rashes which may include blistering or peeling of the skin<br />around your lips, eyes, mouth, nose and genitals; Loss of appetite, skin and eyes becoming<br />yellow in colour, dark-coloured urine, itching, or tender stomach (abdomen). These may be<br />signs of liver problems.<br />Tell your doctor if any of the following side effects gets serious or lasts longer than a few<br />days:<br />Common (affects less than 1 person in 10) - Feeling sick (nausea) and diarrhoea; Increase in<br />the level of some liver enzymes in your blood; Uncommon (affects less than 1 person in 100);<br />Itching and skin rash; Loss of appetite, stomach upset or indigestion (dyspepsia), being sick<br />(vomiting) or pain in your stomach area, feeling bloated (flatulence) or constipation; Headache,<br />feeling dizzy, a spinning feeling (vertigo), feeling sleepy, sleeping problems or feeling nervous;<br />Blood tests may show unusual results due to liver or kidney problems; Changes in the number<br />of white blood cells shown up in the results of some blood tests; General weakness; Changes<br />in the number of other bacteria or fungi may increase, which may need to be treated<br />Rare (affects less than 1 person in 1,000) - Tingly feeling in your hands and feet (paraesthesia)<br />or trembling; Feeling stressed (anxiety), depressed, mental problems, feeling restless<br />(agitation) or feeling confused; Unusual fast beating of your heart or low blood pressure; Joint<br />pain or muscle pain; Bruising and bleeding easily due to a lowering in the number of blood<br />platelets; Low number of white blood cells (called neutropenia); Difficulty breathing or wheezing<br />(bronchospasm); Shortness of breath (dyspnoea); Severe itching or hives (called urticaria);<br />Very rare (affects less than 1 person in 10,000) - Increased sensitivity of your skin to sun and<br />ultraviolet light; Lowering of your blood sugar levels (hypoglycaemia). This is important for<br />people that have diabetes; Problems with your hearing or eyesight or changes in the way things<br />taste and smell; Seeing or hearing things that are not there (hallucinations), change in your<br />opinion and thoughts (psychotic reactions) with a chance of having suicidal thoughts or actions;<br />Loss of circulation (anaphylactic like shock); Muscle weakness. This is important in people with<br />myasthenia gravis (a rare disease of the nervous system); Inflammation of the liver, changes in<br />the way your kidney works and occasional kidney failure which may be due to an allergic kidney<br />reaction called interstitial nephritis; Fever, sore throat and a general feeling of being unwell that<br />does not go away. This may be due to a lowering in the number of white blood cells; Fever and<br />allergic lung reactions; Other side effects include: Lowering in red blood cells (anemia). This<br />can make the skin pale or yellow due to damage of the red blood cells and lowering in the<br />number of all types of blood cells; Exaggerated immune response (hypersensitivity); Sweating<br />too much (hyperhidrosis); Pain, including pain in the back, chest and extremities; Problems in<br />moving and walking; Attacks of porphyria in people who already have porphyria (a very rare<br />metabolic disease); Inflammation of your tubes that carry blood around your body (vessels) due<br />to an allergic reaction.<br />If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet,<br />please tell your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep out of the reach and sight of children.<br />This medicine does not require any special storage conditions but it is best to keep LEVANIX in<br />the original strips and box in a dry place.<br />Store below 30&deg;C.<br />Do not use LEVANIX after the expiry date (EXP) which is stated on the carton and foil.<br />Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist<br />how to dispose of medicines no longer required. These measures will help to protect the<br />environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>What LEVANIX contains<br />LEVANIX 500 (Levofloxacin 500mg):<br />Each film coated tablet contains 512.46 mg of Levofloxacin hemihydrate corresponding to 500 mg of<br />Levofloxacin.<br />The other ingredients are Microcrystalline cellulose, Maize starch, cross povidone, sodium<br />stearyl fumarate, Methyl hydroxypropyl cellulose (hypromellose), Macrogol, Titanium dioxide,<br />ferric oxide yellow, ferric oxide red.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                LEVANIX 500 tablets are light orange coloured, oval shaped, film-coated tablets having '500'
debossed on one side and 'n' debossed on the other side.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Neopharma&nbsp;Abu Dhabi, UAE<br />Levanix is the trademark of Neopharma April 2014<br />V. No. 21531A<br />KEEP MEDICAMENT OUT OF THE REACH OF CHILDREN<br />Plot A-1 89 - 95, ICAD, Mussafah,<br />P.O. Box 72900, Abu Dhabi, UAE.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                04/2014
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>اسم دوائك هو ليفانيكس. يحتوي ليفانيكس على علاج يسمى ليفوفلوكساسين. يندرج هذا الدواء<br />تحت مجموعة العلاجات التي تسمى مضادات حيوية. ليفوفلوكساسين هو مضاد حيوي كينولوني.<br />يعمل عن طريق قتل البكتيريا التي تسبب عدوى داخل جسمك.<br />يمكن استعمال ليفانيكس لعلاج عدوى:<br />&bull; الجيوب<br />&bull; الرئتين، في الأشخاص الذين يعانون من مشاكل تنفسية أو التهاب رئوي منذ زمن طويل<br />&bull; الجهاز البولي، بما في ذلك الكليتين أو المثانة<br />&bull; غدة البروستات، حيث لديك عدوى طويلة الأمد<br />&bull; الجلد وتحت الجلد، بما في ذلك العضلات. وهذه تسمى في بعض الأحيان الأنسجة الرخوة</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>٢. قبل أن تتناول ليفانيكس<br />لا تتناول هذا الدواء وأخبر طبيبك إذا:<br />&bull; كنت تتحسس من الليفوفلوكساسين، أي مضاد حيوي كينولوني آخر مثل موكسيفلوكساسين،<br />سيبروفلوكساسين أو أوفلوكساسين أو أي من مكونات ليفانيكس الأخرى (مذكورة في الفقرة رقم ٦<br />في الأسفل). من ضمن علامات ردود فعل الحساسية: طفح، مشاكل بلع أو تنفس، انتفاخ الشفتين،<br />الحلق أو اللسان.<br />&bull; كان لديك صرع في أي وقت سابق.<br />&bull; كان لديك في وقت سابق مشاكل في أوتارك مثل التهاب الأوتار التي لها علاقة بالعلاج<br />بمضاد حيوي كينولوني. الوتر هو الرابط الذي يربط العضلات بالهيكل العظمي.<br />&bull; كنت طفل أو مراهق في طور النمو.<br />&bull; كنت حاملاً، قد تصبحين حاملاً أو تعتقدين أنك حاملاً.<br />&bull; كنت مرضعة<br />لا تتناول هذا الدواء إن كان أيا من المذكور في الأعلى ينطبق عليك. إن كنت غير متأكداً، أخبر طبيبك أو<br />الصيدلي قبل تناول ليفانيكس.<br />احذر حذرا خاصا عند استعمال ليفانيكس<br />تأكد من طبيبك أو الصيدلي قبل تناولك دوائك إذا:<br />&bull; كنت تبلغ من العمر ٦٥ سنة أو أكثر<br />&bull; كنت تستعمل الكورتيكوستيرويدات، تسمى في بعض الأحيان ستيرويدات (ارجع إلى فقرة &quot;تناول<br />أدوية أخرى&quot; في التالية)<br />&bull; كان لديك صرع في السابق<br />&bull; كان لديك تلف في دماغك بسبب صدمة دماغية أو غيرها من الإصابات الدماغية<br />&bull; كنت تعاني من مشاكل كلوية<br />&bull; كنت تعاني من حالة تسمى نقص إنزيم ٦-فوسفات ديهيدروجينيز. فإنه من المحتمل أن تكون أكثر<br />عرضة لمشاكل خطيرة في دمك عند تناولك لهذا الدواء<br />&bull; كان لديك مشاكل صحية عقلية في السابق<br />&bull; كان لديك مشاكل قلبية في السابق<br />&bull; كنت تعاني من داء السكري<br />&bull; كان لديك مشاكل كبدية في السابق<br />إن كنت غير متأكداً إن كان أيا من المذكور في الأعلى ينطبق عليك أم لا، أخبر طبيبك أو الصيدلي قبل<br />تناول ليفانيكس.<br />تناول أدوية أخرى<br />أخبر طبيبك إن كنت تتناول أو تناولت حديثا أدوية أخرى. وهذا يشمل الأدوية التي اشتريتها بدون وصفة<br />طبية، بما في ذلك الأدوية العشبية. وذلك لأن ليفانيكس قد يؤثر على عمل بعض الأدوية. كما أن بعض<br />الأدوية قد تؤثر على عمل ليفانيكس.<br />على وجه الخصوص، أخبر طبيبك إن كنت تتناول أياً من الأدوية التالية. وذلك لأنها قد تزيد فرصة<br />حدوث آثار جانبية عند تناولها مع أقراص ليفانيكس:<br />&bull; الكورتيكوستيرويدات التي تسمى في بعض الأحيان ستيرويدات والتي تستعمل لعلاج الالتهاب. من<br />المحتمل أن تكون أكثر عرضة للإصابة بالتهاب و/أو تحطم الأوتار.<br />&bull; الوورفارين الذي يستعمل لتخفيف كثافة الدم. من المحتمل أن تكون أكثر عرضة للإصابة بنزيف. قد<br />يحتاج طبيبك إلى عمل فحوصات دموية منتظمة للكشف على كفاءة الدم في التخثر.<br />&bull; الثيوفيللين الذي يستعمل في حالات مشاكل التنفس. من المحتمل أن تكون أكثر عرضة<br />للإصابة بصرع إن كنت تتناول ليفانيكس.<br />&bull; الأدوية المضادة للالتهاب الغير ستيرويدية (إن إس إيه آي دي إس) التي تستعمل لعلاج الألم<br />والالتهاب مثل الأسبيرين، الأيبوبروفين، فينبيوفين، كيتوبروفين وإندوميثاسين. من المحتمل أن تكون<br />أكثر عرضة للإصابة بصرع إن كنت تتناول ليفانيكس.<br />&bull; السيكلوسبورين الذي يستعمل بعد نقل الأعضاء. من المحتمل أن تكون أكثر عرضة<br />للإصابة بالآثار الجانبية التي تسببها سيكلوسبورين.<br />&bull; الأدوية التي تعرف بتأثيرها على ضربات القلب. ويضم هذا الأدوية التي تستعمل في حالة<br />عدم انتظام ضربات القلب (مضادات اللانتظامية مثل كينيدين وأميودارون)، والأدوية التي<br />تستعمل للاكتئاب (مضادات الاكتئاب ثلاثية الحلقات مثل أميتريبتيلين وإميبرامين) والأدوية<br />المضادة للعدوى البكتيرية (المضادات الحيوية الماكرولايدية مثل إريثرومايسين، أزيثرومايسين<br />وكلاريثرومايسين).<br />&bull; البروبينسايد الذي يستعمل لعلاج النقرس، والسيميتيدين الذي يستعمل لعلاج التقرحات<br />وحموضة المعدة. يجب الحذر حذرا خاصاً عند تناول أي من هذين الدوائين مع ليفانيكس. إن كنت<br />تعاني من مشاكل كلوية، قد يرغب طبيبك أن يعطيك جرعة أقل.<br />لا تتناول ليفانيكس في نفس وقت تناولك للأدوية التالية. لأنها قد تؤثر على طريقة عمل<br />ليفانيكس:<br />&bull; أقراص الحديد (لفقر الدم)، مضادات الحموضة التي تحتوي على مغنيسيوم أو ألومنيوم (لحموضة<br />وحرقة المعدة) أو سكرالفيت (لتقرحات المعدة). ارجع إلى الفقرة التالية &quot;إن كنت تتناول أقراص<br />الحديد، مضادات الحموضة أو سكرالفيت&quot;.<br />فحوصات البول للمواد الأفيونية<br />قد تظهر فحوصات البول نتائج إيجابية خاطئة لمسكنات الألم القوية التي تسمى &quot;الأفيونيات&quot; لدى<br />الأشخاص الذين يتناولون ليفانيكس. إذا أراد طبيبك أن ينجز فحص بول، أخبره أنك تتناول ليفانيكس.<br />الحمل والإرضاع<br />لا تتناول هذا الدواء إذا: .C فئة السلامة أثناء الحمل<br />&bull; كنت حاملاً، قد تصبحين حاملا أو تعتقدين أنك حاملاً.<br />&bull; كنت مرضعة أو تنوين الرضاعة.<br />اطلبي النصيحة من طبيبك أو الصيدلي قبل تناولك أي دواء إن كنت حاملاً أو مرضعة.<br />القيادة واستعمال المكائن<br />قد تعاني من آثار جانبية بعد تناول هذا الدواء، بما في ذلك الشعور بدوار، نعاس، الشعور بدوخة أو تغيرات<br />بصرية. بعض هذه الآثار الجانبية يؤثر على قدرتك على التركيز أو سرعة التفاعل. إذا حدث هذا، لا تنصح<br />بالقيادة أو البدء بالأعمال التي تحتاج إلى تركيز عالي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>تناول ليفانيكس دائما كما أخبرك طبيبك تماماً. يجب أن تسأل طبيبك أو الصيدلي إن كنت غير متأكداً.<br />تناول هذا الدواء<br />&bull; تناول هذا الدواء عن طريق الفم.<br />&bull; ابلع الأقراص كاملة مع شرب الماء.<br />&bull; يمكن تناول الأقراص أثناء الوجبات أو في أي وقت بين الوجبات.<br />احفظ جلدك من أشعة الشمس<br />لا تتعرض إلى أشعة الشمس المباشرة أثناء تناولك لهذا الدواء. وهذا لأن جلدك سوف يصبح أكثر<br />حساسية من أشعة الشمس وقد يحترق، يصاب بالتوخز أو بثور شديدة إذا لم تأخذ بعين الاعتبار<br />الاحتياطات التالية:<br />&bull; تأكد من استعمال كريم قوي واقي من الشمس.<br />&bull; البس دائما غطاء رأس وملابس تغطي الأذرع والأقدام.<br />&bull; تجنب سرير التشمس.<br />إن كنت تتناول أقراص الحديد، مضادات الحموضة أو سكرالفيت<br />&bull; لا تتناول هذه الأدوية في نفس وقت تناول ليفانيكس، تناول قرصك قبل أو بعد ساعتين على الأقل من<br />تناولك لليفانيكس.<br />كم تتناول<br />&bull; سوف يقرر طبيبك كم قرص ليفانيكس يجب أن تتناول.<br />&bull; سوف تحدد الجرعة اعتمادا على نوع العدوى التي تعاني منها ومكانها في جسمك.<br />&bull; سوف تعتمد مدة علاجك على شدة العدوى التي تعاني منها.<br />&bull; إن كنت تشعر بأن الدواء الذي تتناوله ضعيف أو قوي جدا، لا تغير الجرعة من نفسك، ولكن اسأل<br />طبيبك.<br />البالغين وكبار السن<br />التهاب الجيوب الأنفية<br />قرص واحد ليفانيكس ٥٠٠ ملجم مرة كل يوم.<br />الرئتين :<br />الالتهاب الرئوي<br />قرص ليفانيكس ٥٠٠ ملجم مرة أو مرتين كل يوم.<br />في الأشخاص الذين يعانون من مشاكل تنفسية طويل الأمد<br />نصف قرص أو قرص واحد ليفانيكس ٥٠٠ ملجم مرة كل يوم.<br />الجهاز البولي، بما في ذلك الكليتين أو المثانة<br />نصف قرص ليفانيكس ٥٠٠ ملجم كل يوم.<br />غدة البروستات<br />قرص ليفانيكس ٥٠٠ ملجم مرة كل يوم.<br />الجلد وتحت الجلد، بما في ذلك العضلات&nbsp;نصف قرص أو قرص ليفانيكس ٥٠٠ ملجم مرة أو مرتين كل يوم.<br />البالغون الذين يعانون من مشاكل كلوية<br />قد يقلل طبيبك الجرعة.<br />الأطفال والمراهقون<br />يجب عدم إعطاء هذا الدواء للأطفال أو المراهقين.<br />إذا تناولت ليفانيكس أكثر مما يجب<br />إذا تناولت عن طريق الخطأ أقراص ليفانيكس أكثر مما يجب، أخبر الطبيب أو اطلب النصيحة الطبية فوراً.<br />خذ معك عبوة الدواء لكي يعرف طبيبك ماذا تناولت. قد تحدث الآثار التالية:<br />صرع، الشعور بالارتباك، دوار، نقص الوعي ومشاكل قلبية &ndash; اضطراب ضربات القلب والشعور بالتقيؤ<br />(غثيان).<br />إذا نسيت تناول ليفانيكس<br />إذا نسيت تناول جرعة ليفانيكس، تناولها بمجرد تذكرك لها إلا إذا كان وقت الجرعة التالية قريبا. لا<br />تضاعف الجرعة التالية لتعويض الجرعة التي نسيتها.<br />إذا توقفت عن تناول ليفانيكس<br />لا تتوقف عن تناول ليفانيكس حتى لو شعرت بتحسن. من الضروري أن تكمل مدة العلاج التي وصفها<br />لك طبيبك. إذا توقفت عن تناول ليفانيكس قبل الأوان قد تعاود العدوى الظهور، وقد تصبح حالتك أسوأ<br />أو قد تصبح البكتيريا مقاومة للعلاج.<br />إذا كانت لديك أي أسئلة أخرى فيما يخص هذا الدواء، اسأل طبيبك أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>كما هو الحال في كل الأدوية، قد يسبب ليفانيكس آثار جانبية، على الرغم من أنها لا تحدث عند كل<br />شخص. هذه الآثار خفيفة أو متوسطة وتختفي غالبا بعد وقت قصير.<br />توقف عن تناول ليفانيكس واذهب إلى الطبيب أو المستشفى فوراً إذا لاحظت الآثار التالية:<br />نادرة جداً (تظهر في أقل من شخص من ضمن ١٠٠٠٠ شخص)<br />&bull; ردود فعل حساسية. قد تضم العلامات التالية: طفح، مشاكل بلع أو تنفس، انتفاخ الشفاه، الوجه،<br />الحلق أو اللسان.<br />توقف عن تناول ليفانيكس واذهب إلى الطبيب أو المستشفى فوراً إذا لاحظت ظهور أي من الآثار<br />الجانبية الخطيرة التالية &ndash; قد تحتاج الى عناية طبية طارئة:<br />نادرة (تظهر في أقل من ١ شخص من ضمن ١٠٠٠ شخص)<br />&bull; إسهال مائي التي قد يصاحبه دم، مع احتمال حدوث تقلصات معدية وحرارة مرتفعة. وقد يكون هذا<br />علامة لمشكلة معوية حادة.<br />&bull; ألم والتهاب في الأوتار. يصاب غالباً وتر العرقوب وفي بعض الحالات قد يتمزق الوتر.<br />&bull; تخلجات<br />نادرة جداً (تحدث في أقل من ١ شخص من ضمن ١٠٠٠٠ شخص)<br />&bull; الشعور باحتراق، تنمل، ألم أو تخدر. قد تكون هذه علامات لاضطرابات تسمى اعتلال عصبي.<br />أخرى:<br />&bull; طفح جلدي شديد مع احتمال حدوث تقرح أو تقشر حول الشفاه، العيون، الفم، الأنف والأعضاء<br />التناسلية.<br />&bull; نقص الشهية، اصفرار لون الجلد والعيون، لون البول داكن، حكة، أو انتفاخ البطن. قد تكون هذه<br />علامات مشاكل كبدية.<br />أخبر طبيبك إذا أي من الآثار الجانبية التالية أصبح شديداً أو طال بقاؤه لعدة أيام:<br />شائعة (تظهر في أقل من ١ شخص من ضمن ١٠ أشخاص)<br />&bull; الشعور بالتقيؤ (الغثيان) و الإسهال.<br />&bull; زيادة في مستويات بعض إنزيمات الكبد في الدم.<br />غير شائعة (تظهر في أقل من ١ شخص من ضمن ١٠٠ شخص)<br />&bull; حكة وطفح جلدي.<br />&bull; فقدان الشهية، اضطراب معدي أو عسر الهضم، التقيؤ أو ألم في منطقة المعدة، الانتفاخ أو<br />الإمساك.<br />&bull; صداع، الشعور بدوار، دوخة، الشعور بنعاس، مشاكل في النوم أو الشعور بالعصبية.<br />&bull; قد تظهر فحوصات الدم نتائج غير طبيعية نتيجة مشاكل كبدية أو كلوية.<br />&bull; ظهور تغيرات في عدد خلايا الدم البيضاء في نتائج بعض فحوصات الدم.<br />&bull; ضعف عام.<br />&bull; قد تزيد التغيرات في عدد بكتيريا أخرى أو فطريات، والتي يجب علاجها.<br />نادرة (تظهر في أقل من ١ شخص من ضمن ١٠٠٠ شخص).<br />&bull; لشعور بتنمل في الأيدي والأقدام وارتجاف.<br />&bull; قلق، اكتئاب، مشاكل عقلية، هيجان أو الشعور بارتباك.<br />&bull; ضربات قلبية سريعة غير طبيعية أو ضغط دم منخفض.<br />&bull; ألم مفاصل أو ألم عضلات.<br />&bull; سهولة حدوث كدمات ونزف نتيجة نقص عدد الصفيحات الدموية.<br />&bull; نقص عدد خلايا الدم البيضاء.<br />&bull; صعوبة في التنفس أو أزيز الصدر (تشنج قصبي).<br />&bull; قصر النفس (ضيق التنفس).<br />&bull; حكة شديدة أو الشرى (تسمى أورتيكاريا).<br />نادرة جداً (تظهر في أقل من ١ شخص من ضمن ١٠٠٠٠ شخص).<br />&bull; زيادة حساسية الجلد للشمس والأشعة فوق البنفسجية.<br />&bull; نقص مستويات سكر الدم (هيبوغلايسيميا). وهذا مهم لدى الأشخاص المصابين بداء السكري.<br />&bull; مشاكل في السمع أو البصر أو اختلافات في التذوق وشم الروائح.<br />&bull; رؤية أو سماع أشياء غير حقيقية (هلوسة)، تغير في الآراء والأفكار (ردود فعل نفسية) مع احتمال<br />وجود أفكار أو أعمال انتحار.<br />&bull; فقدان تدفق الدم (ما يشبه الصدمة التأقية).<br />&bull; ضعف العضلات. وهذا مهم لدى الأشخاص المصابين بالوهن العضلي الوبيل (مرض نادر للجهاز<br />العصبي).<br />&bull; التهاب الكبد، تغيرات في طريقة عمل الكلية وفشل كلوي عرضي والتي قد تكون بسبب ردود فعل<br />حساسية كلوية تسمى التهاب الكلى الخلالي.<br />&bull; حمى، التهاب البلعوم وشعور عام بالإعياء. وهذا قد يكون بسبب نقص في عدد خلايا الدم البيضاء.<br />&bull; حمى وردود فعل حساسية رئوية.<br />وتشمل الآثار الجانبية الأخرى:<br />&bull; نقص في كريات الدم الحمراء (أنيميا). وقد يجعل هذا الجلد شاحباً أو أصفراً نتيجة تحطم في كريات<br />الدم الحمراء ونقص في عدد جميع أنواع خلايا الدم.<br />&bull; زيادة النشاط المناعي (فرط الحساسية).<br />&bull; تعرق شديد<br />&bull; ألم، بما في ذلك ألم في الظهر، الصدر والأطراف.<br />&bull; مشاكل في الحركة والمشي.<br />&bull; نوبات بورفيريا في الأشخاص الذين يعانون من البورفيريا (مرض أيضي نادر جداً).<br />&bull; التهاب الأوعية الدموية الناقلة للدم نتيجة ردود فعل حساسية.<br />إذا أصبح أياً من الآثار الجانبية شديداً، أو إذا لاحظت ظهور آثار جانبية غير مذكورة في هذه النشرة، لطفا<br />أخبر طبيبك أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>يحفظ بعيدا عن متناول الأطفال.<br />لا يحتاج هذا الدواء الى ظروف تخزين خاصة ولكن من الأفضل إبقاؤه في عبوته الأصلية في مكان جاف.<br />يحفظ عند درجة حرارة أقل من ٣٠ &deg;م.<br />.&quot;EXP&quot; لا تستعمله بعد تاريخ الانتهاء المذكور على العبوة أو الشريط بعد<br />يجب عدم التخلص من الأدوية عن طريق المياه القذرة أو النفايات المنزلية. اسأل الصيدلي عن كيفية<br />التخلص من الأدوية التي ليس بحاجة اليها. هذه المقاييس سوف تساعد لحماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>ماذا يحتوي ليفانيكس<br />ليفانيكس ٥٠٠ (ليفوفلوكساسين ٥٠٠ ملجم):<br />كل قرص مغلف يحتوي على ٥١٢٫٤٦ ملجم من ليفوفلوكساسين هيميهيدريت مكافئة ل ٥٠٠ ملجم<br />من ليفوفلوكساسين.<br />المحتويات الأخرى هي سيليلوز دقيق البلورة، نشا ذرة، كروس بوفيدون، فومارات ستيريل الصوديوم، مثيل<br />هيدروكسيبروبيل سيليلوز (هيبروميللوز)، ماكروغول، ثاني أكسيد التيتانيوم، أكسيد الحديد الأصفر،<br />أكسيد الحديد الأحمر.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p>ليفانيكس ٥٠٠ أقراص مغلفة لونها برتقالي فاتح، شكلها بيضاوي محفور عليها &quot; 500 &quot; من جهة و<br />من الجهة الأخرى.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>نيوفارما&nbsp;أبوظبي، ا.ع.م<br />ليفانيكس علامة تجارية لنيوفارما إبريل ٢٠١٤<br />V.No. 21 5 31A<br />يحفظ الدواء بعيداً عن متناول الأطفال<br />٩٥ ، مدينة أبوظبي -٨٩ قطعة رقم إيه- ١<br />الصناعية، مصفح، ص.ب. ٧٢٩٠٠ ، أبوظبي، إ.ع.م.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            04/204
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Levanix Tablets 500 mg
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each film coated tablet contains 512.46 mg of Levofloxacin Hemihydrate equivalent to 500 mg of Levofloxacin.
‘for full list of excipients, see section 6.1’.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Film Coated Tablets
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Levanix is indicated in adults for the treatment of the following infections:<br />&bull; Acute bacterial sinusitis<br />&bull; Acute exacerbations of chronic bronchitis<br />&bull; Community-acquired pneumonia<br />&bull; Complicated skin and soft tissue infections<br />For the above-mentioned infections Levanix should be used only when it is considered inappropriate to use antibacterial agents that are commonly recommended for the initial treatment of these infections.<br />&bull; Pyelonephritis and complicated urinary tract infections<br />&bull; Chronic bacterial prostatitis<br />&bull; Uncomplicated cystitis<br />&bull; Inhalation Anthrax: post exposure prophylaxis and curative treatment<br />Levanix may also be used to complete a course of therapy in patients who have shown improvement during initial treatment with intravenous levofloxacin.<br />Consideration should be given to official guidance on the appropriate use of antibacterial agents.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Levanix tablets are administered once or twice daily. The dosage depends on the type and severity of the infection and the susceptibility of the presumed causative pathogen.<br />Levanix tablets may also be used to complete a course of therapy in patients who have shown improvement during initial treatment with intravenous levofloxacin; given the bioequivalence of the parenteral and oral forms, the same dosage can be used.<br />Posology<br />The following dose recommendations can be given for Levanix:<br />Dosage in patients with normal renal function (creatinine clearance &gt; 50 ml/min)<br />Indication<br />Daily dose regimen<br />(according to severity)<br />Duration of treatment<br />(according to severity)<br />Acute bacterial sinusitis<br />500 mg once daily<br />10 - 14 days<br />Acute bacterial exacerbations of chronic bronchitis<br />500 mg once daily<br />7 - 10 days<br />Community-acquired pneumonia<br />500 mg once or twice daily<br />7 - 14 days<br />Pyelonephritis<br />500 mg once daily<br />7 - 10 days<br />Complicated urinary tract infections<br />500 mg once daily<br />7 &ndash; 14 days<br />Uncomplicated cystitis<br />250mg once daily<br />3 days<br />Chronic bacterial prostatitis<br />500 mg once daily<br />28 days<br />Complicated skin and soft tissue infections<br />500 mg once or twice daily<br />7 - 14 days<br />Inhalation Anthrax<br />500 mg once daily<br />8 weeks</p><p>Special populations<br />Impaired renal function (creatinine clearance &le; 50 ml/min)<br />Dose regimen<br />250 mg/24 h<br />500 mg/24 h<br />500 mg/12 h<br />Creatinine clearance<br />first dose: 250 mg<br />first dose: 500 mg<br />first dose: 500 mg<br />50-20 ml/min<br />then: 125 mg/24 h<br />then: 250 mg/24 h<br />then: 250 mg/12 h</p><p>19-10 ml/min<br />then: 125 mg/48 h<br />then: 125 mg/24 h<br />then: 125 mg/12 h<br />&lt; 10 ml/min (including haemodialysis and CAPD) 1<br />then: 125 mg/48 h<br />then: 125 mg/24 h<br />then: 125 mg/24 h<br />1 No additional doses are required after haemodialysis or continuous ambulatory peritoneal dialysis (CAPD).<br />Impaired liver function:<br />No adjustment of dose is required since levofloxacin is not metabolized to any relevant extent by the liver and is mainly excreted by the kidneys.<br />Elderly Population:<br />No adjustment of dose is required in the elderly, other than that imposed by consideration of renal function.<br />Paediatric population:<br />Levanix is contraindicated in children and growing adolescents.<br />Method of administration<br />Levanix tablets should be swallowed without crushing and with sufficient amount of liquid. The tablets may be taken during meals or between meals.<br />Levanix tablets should be taken at least two hours before or after iron salts, zinc salts, magnesium- or aluminium-containing antacids, or didanosine (only didanosine formulations with aluminium or magnesium containing buffering agents), and sucralfate administration, since reduction of absorption can occur.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Levofloxacin tablets must not be used:
• in patients hypersensitive to levofloxacin or other quinolones or any of the excipients listed in section 6.1,
• in patients with epilepsy,
• in patients with history of tendon disorders related to fluoroquinolone administration,
• in children or growing adolescents,
during pregnancy,
• in breast-feeding women.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Methicillin-resistant S. aureus are very likely to possess co-resistance to fluoroquinolones, including levofloxacin. Therefore levofloxacin is not recommended for the treatment of known or suspected MRSA infections unless laboratory results have confirmed susceptibility of the organism to levofloxacin (and commonly recommended antibacterial agents for the treatment of MRSA-infections are considered inappropriate).<br />Levofloxacin may be used in the treatment of Acute Bacterial Sinusitis and Acute Exacerbation of Chronic Bronchitis when these infections have been adequately diagnosed.<br />Resistance to fluoroquinolones of E. coli &ndash; the most common pathogen involved in urinary tract infections &ndash; varies across the European Union. Prescribers are advised to take into account the local prevalence of resistance in E. coli to fluoroquinolones.<br />Inhalation Anthrax: Use in human is based on in vitro Bacillus anthracis susceptibility data and on animal experimental data together with limited human data. Treating physicians should refer to national and/or international consensus documents regarding the treatment of anthrax.<br />Tendinitis and Tendon Rupture<br />Tendinitis may rarely occur. It most frequently involves the Achilles tendon and may lead to tendon rupture. Tendinitis and tendon rupture, sometimes bilateral, may occur within 48 hours of starting treatment with levofloxacin and have been reported up to several months after discontinuation of treatment. The risk of tendinitis and tendon rupture is increased in patients aged over 60 years, in patients receiving daily doses of 1000 mg and in patients using corticosteroids.<br />The daily dose should be adjusted in elderly patients based on creatinine clearance. Close monitoring of these patients is therefore necessary if they are prescribed levofloxacin. All patients should consult their physician if they experience symptoms of tendinitis. If tendinitis is suspected, treatment with levofloxacin must be halted immediately, and appropriate treatment (e.g. immobilisation) must be initiated for the affected tendon.</p><p>Clostridium difficile-associated disease<br />Diarrhoea, particularly if severe, persistent and/or bloody, during or after treatment with levofloxacin (including several weeks after treatment), may be symptomatic of Clostridium difficile-associated disease (CDAD). CDAD may range in severity from mild to life threatening, the most severe form of which is pseudomembranous colitis. It is therefore important to consider this diagnosis in patients who develop serious diarrhoea during or after treatment with levofloxacin. If CDAD is suspected or confirmed, levofloxacin should be stopped immediately and appropriate treatment initiated without delay. Anti-peristaltic medicinal products are contraindicated in this clinical situation.<br />Patients predisposed to seizures<br />Quinolones may lower the seizure threshold and may trigger seizures. Levofloxacin is contraindicated in patients with a history of epilepsy and, as with other quinolones, should be used with extreme caution in patients predisposed to seizures or concomitant treatment with active substances that lower the cerebral seizure threshold, such as theophylline. In case of convulsive seizures, treatment with levofloxacin should be discontinued.<br />Patients with G-6- phosphate dehydrogenase deficiency<br />Patients with latent or actual defects in glucose-6-phosphate dehydrogenase activity may be prone to haemolytic reactions when treated with quinolone antibacterial agents. Therefore, if levofloxacin has to be used in these patients, potential occurrence of haemolysis should be monitored.<br />Patients with renal impairment<br />Since levofloxacin is excreted mainly by the kidneys, the dose of Levanix should be adjusted in patients with renal impairment.<br />Hypersensitivity reactions<br />Levofloxacin can cause serious, potentially fatal hypersensitivity reactions (e.g. angioedema up to anaphylactic shock), occasionally following the initial dose. Patients should discontinue treatment</p><p>immediately and contact their physician or an emergency physician, who will initiate appropriate emergency measures.<br />Severe bullous reactions<br />Cases of severe bullous skin reactions such as Stevens-Johnson syndrome or toxic epidermal necrolysis have been reported with levofloxacin. Patients should be advised to contact their doctor immediately prior to continuing treatment if skin and/or mucosal reactions occur.<br />Dysglycaemia<br />As with all quinolones, disturbances in blood glucose, including both hypoglycaemia and hyperglycaemia have been reported, usually in diabetic patients receiving concomitant treatment with an oral hypoglycaemic agent (e.g., glibenclamide) or with insulin. Cases of hypoglycaemic coma have been reported. In diabetic patients, careful monitoring of blood glucose is recommended.<br />Prevention of Photosensitisation<br />Photosensitisation has been reported with levofloxacin. It is recommended that patients should not expose themselves unnecessarily to strong sunlight or to artificial UV rays (e.g. sunray lamp, solarium), during treatment and for 48 hours following treatment discontinuation in order to prevent photosensitisation.<br />Patients treated with Vitamin K antagonists<br />Due to possible increase in coagulation tests (PT/INR) and/or bleeding in patients treated with levofloxacin in combination with a vitamin K antagonist (e.g. warfarin), coagulation tests should be monitored when these drugs are given concomitantly.<br />Psychotic reactions<br />Psychotic reactions have been reported in patients receiving quinolones, including levofloxacin. In very rare cases these have progressed to suicidal thoughts and self-endangering behaviour- sometimes after only a single dose of levofloxacin. In the event that the patient develops these reactions, levofloxacin should be discontinued and appropriate measures instituted.Caution is recommended if levofloxacin is to be used in psychotic patients or in patients with history of psychiatric disease.<br />QT interval prolongation<br />Caution should be taken when using fluoroquinolones, including levofloxacin, in patients with known risk factors for prolongation of the QT interval such as, for example:<br />- congenital long QT syndrome<br />- concomitant use of drugs that are known to prolong the QT interval (e.g. Class IA and III antiarrhythmics, tricyclic antidepressants, macrolides, antipsychotics).<br />- uncorrected electrolyte imbalance (e.g. hypokalemia, hypomagnesemia)<br />- cardiac disease (e.g. heart failure, myocardial infarction, bradycardia)<br />Elderly patients and women may be more sensitive to QTc-prolonging medications. Therefore, caution should be taken when using fluoroquinolones, including levofloxacin, in these populations.<br />Peripheral neuropathy<br />Peripheral sensory neuropathy and peripheral sensory motor neuropathy have been reported in patients receiving fluoroquinolones, including levofloxacin, which can be rapid in its onset. Levofloxacin should be discontinued if the patient experiences symptoms of neuropathy in order to prevent the development of an irreversible condition.<br />Hepatobiliary disorders<br />Cases of hepatic necrosis up to fatal hepatic failure have been reported with levofloxacin, primarily in patients with severe underlying diseases, e.g. sepsis. Patients should be advised to stop treatment and contact their doctor if signs and symptoms of hepatic disease develop such as anorexia, jaundice, dark urine, pruritus or tender abdomen.<br />Exacerbation of myasthenia gravis<br />Fluoroquinolones, including levofloxacin, have neuromuscular blocking activity and may exacerbate muscle weakness in patients with myasthenia gravis. Post marketing serious adverse reactions, including deaths and the requirement for respiratory support, have been associated with&nbsp;fluoroquinolone use in patients with myasthenia gravis. Levofloxacin is not recommended in patients with a known history of myasthenia gravis.<br />Vision disorders<br />If vision becomes impaired or any effects on the eyes are experienced, an eye specialist should be consulted immediately.<br />Superinfection<br />The use of levofloxacin, especially if prolonged, may result in overgrowth of non-susceptible organisms. If superinfection occurs during therapy, appropriate measures should be taken.<br />Interference with laboratory tests<br />In patients treated with levofloxacin, determination of opiates in urine may give false-positive results. It may be necessary to confirm positive opiate screens by more specific method.<br />Levofloxacin may inhibit the growth of Mycobacterium tuberculosis and, therefore, may give false-negative results in the bacteriological diagnosis of tuberculosis.<br />Epidemiologic studies report an increased risk of aortic aneurysm and dissection after intake of fluoroquinolones, particularly in the older population.<br />Therefore, fluoroquinolones should only be used after careful benefit-risk assessment and after consideration of other therapeutic options in patients with positive family history of aneurysm disease, or in patients diagnosed with pre-existing aortic aneurysm and/or aortic dissection, or in presence of other risk factors or conditions predisposing for aortic aneurysm and dissection (e.g. Marfan syndrome, vascular Ehlers-Danlos syndrome, Takayasu arteritis, giant cell arteritis, Behcet&rsquo;s disease, hypertension, known atherosclerosis).<br />In case of sudden abdominal, chest or back pain, patients should be advised to immediately consult a physician in an emergency department.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Effect of other medicinal products on Levanix<br />Iron salts, zinc salts, magnesium- or aluminium-containing antacids, didanosine<br />Levofloxacin absorption is significantly reduced when iron salts, or magnesium- or aluminium- containing antacids, or didanosine (only didanosine formulations with aluminium or magnesium&nbsp;containing buffering agents) are administered concomitantly with Levanix tablets. Concurrent administration of fluoroquinolones with multi-vitamins containing zinc appears to reduce their oral absorption. It is recommended that preparations containing divalent or trivalent cations such as iron salts, zinc salts or magnesium- or aluminium-containing antacids, or didanosine (only didanosine formulations with aluminium or magnesium containing buffering agents) should not be taken 2 hours before or after Levanix tablet administration. Calcium salts have a minimal effect on the oral absorption of levofloxacin.<br />Sucralfate<br />The bioavailability of Levanix tablets is significantly reduced when administered together with sucralfate. If the patient is to receive both sucralfate and Levanix, it is best to administer sucralfate 2 hours after the Levanix tablet administration.<br />Theophylline, fenbufen or similar non-steroidal anti-inflammatory drugs<br />No pharmacokinetic interactions of levofloxacin were found with theophylline in a clinical study. However a pronounced lowering of the cerebral seizure threshold may occur when quinolones are given concurrently with theophylline, non-steroidal anti-inflammatory drugs, or other agents which lower the seizure threshold.<br />Levofloxacin concentrations were about 13% higher in the presence of fenbufen than when administered alone.<br />Probenecid and cimetidine<br />Probenecid and cimetidine had a statistically significant effect on the elimination of levofloxacin. The renal clearance of levofloxacin was reduced by cimetidine (24%) and probenecid (34%).<br />This is because both drugs are capable of blocking the renal tubular secretion of levofloxacin. However, at the tested doses in the study, the statistically significant kinetic differences are unlikely to be of clinical relevance.<br />Caution should be exercised when levofloxacin is coadministered with drugs that affect the tubular renal secretion such as probenecid and cimetidine, especially in renally impaired patients.<br />Other relevant information&nbsp;Clinical pharmacology studies have shown that the pharmacokinetics of levofloxacin were not affected to any clinically relevant extent when levofloxacin was administered together with the following drugs: calcium carbonate, digoxin, glibenclamide, ranitidine.<br />Effect of Levanix on other medicinal products<br />Ciclosporin<br />The half-life of ciclosporin was increased by 33% when coadministered with levofloxacin.<br />Vitamin K antagonists<br />Increased coagulation tests (PT/INR) and/or bleeding, which may be severe, have been reported in patients treated with levofloxacin in combination with a vitamin K antagonist (e.g. warfarin). Coagulation tests, therefore, should be monitored in patients treated with vitamin K antagonists.<br />Drugs known to prolong QT interval<br />Levofloxacin, like other fluoroquinolones, should be used with caution in patients receiving drugs known to prolong the QT interval (e.g. Class IA and III antiarrhythmics, tricyclic antidepressants, macrolides, antipsychotics).<br />Other relevant information<br />In a pharmacokinetic interaction study, levofloxacin did not affect the pharmacokinetics of theophylline (which is a probe substrate for CYP1A2), indicating that levofloxacin is not a CYP1A2 inhibitor.<br />Other forms of interactions<br />Food<br />There is no clinically relevant interaction with food. Levanix tablets may therefore be administered regardless of food intake.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pregnancy<br />Pregnancy Category C. There are limited amount of data from the use of levofloxacin in pregnant women. Animal studies do not indicate direct or indirect harmful effects with respect to&nbsp;reproductive toxicity. However in the absence of human data and due to that experimental data suggest a risk of damage by fluoroquinolones to the weight-bearing cartilage of the growing organism, levofloxacin must not be used in pregnant women .<br />Breast-feeding<br />Levanix is contraindicated in breast-feeding women. There is insufficient information on the excretion of levofloxacin in human milk; however, other fluoroquinolones are excreted in breast milk.<br />In the absence of human data and due to that experimental data suggest a risk of damage by fluoroquinolones to the weight-bearing cartilage of the growing organism, levofloxacin must not be used in breast-feeding women.<br />Fertility<br />Levofloxacin caused no impairment of fertility or reproductive performance in rats.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Some undesirable effects (e.g. dizziness/vertigo, drowsiness, visual disturbances) may impair the patient&#39;s ability to concentrate and react, and therefore may constitute a risk in situations where these abilities are of special importance (e.g. driving a car or operating machinery).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The information given below is based on data from clinical studies in more than 8300 patients and on extensive post marketing experience.<br />Frequencies are defined using the following convention: very common (&ge;1/10), common (&ge;1/100, &lt;1/10), uncommon (&ge;1/1000, &lt;1/100), rare (&ge;1/10000, &lt;1/1000), very rare (&lt;1/10000), not known (cannot be estimated from the available data).<br />Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness.</p><p>System organ class<br />Common (-1/100 to<br />&lt;1/10 )<br />Uncommon (-1/1,000 to<br />&lt;1/100<br />Rare<br />(-1/10,000 to &lt;1/1,000)<br />Not known (cannot be estimated from available data)<br />Infections and infestations<br />Fungal infection<br />Including Candida infection<br />Pathogen resistanc<br />Blood and lymphatic system disorders<br />Leukopenia Eosinophilia<br />Thrombocytopenia Neutropenia<br />Pancytopenia Agranulocytosis Haemolytic anaemia<br />Immune system disorders<br />Angioedema<br />Hypersensitivity (see section 4.4)<br />Anaphylactic shocka<br />Anaphylactoid shocka (see section 4.4)<br />Metabolism and nutrition disorders<br />Anorexia<br />Hypoglycaemia particularly in diabetic patients (see section 4.4)<br />Hyperglycaemia<br />Hypoglycaemic coma (see section 4.4)<br />Psychiatric disorders<br />Insomnia<br />Anxiety Confusional state Nervousness<br />Psychotic reactions (with<br />e.g. hallucination, paranoia) Depression<br />Agitation Abnormal dreams Nightmares<br />Psychotic disorders with self- endangering behaviour including suicidal ideation or suicide attempt (see section 4.4)<br />Nervous system disorders<br />Headache Dizziness<br />Somnolence Tremor Dysgeusia<br />Convulsion (see sections<br />4.3 and 4.4) Paraesthesia<br />Peripheral sensory neuropathy (see section 4.4)<br />Peripheral sensory motor neuropathy (see section 4.4)<br />Parosmia including anosmia Dyskinesia Extrapyramidal disorder Ageusia Syncope<br />Benign intracranial hypertension<br />Eye disorders<br />Visual disturbances such as blurred vision (see section 4.4)<br />Transient vision loss (see section 4.4), uveitis</p><p>Ear and Labyrinth disorders<br />Vertigo<br />Tinnitus<br />Hearing loss<br />Hearing impaired<br />Cardiac disorders<br />Tachycardia, Palpitation<br />Ventricular tachycardia, which may result in cardiac arrest Ventricular arrhythmia and torsade de pointes (reported predominantly in patients with risk factors of QT prolongation),<br />Electrocardiogram QT prolonged (see sections 4.4 and 4.9)<br />Vascular disorders<br />Applies to iv form only:<br />Phlebitis<br />Hypotension<br />Respiratory, thoracic and mediastinal disorders<br />Dyspnoea<br />Bronchospasm, Pneumonitis allergic<br />Gastrointestinal disorders<br />Diarrhoea<br />Vomiting<br />Nausea<br />Abdominal pain<br />Dyspepsia<br />Flatulence<br />Constipation<br />Diarrhoea &ndash;haemorrhagic which in very rare cases may be indicative of enterocolitis,<br />including pseudomembranous<br />colitis (see section 4.4)<br />Pancreatitis<br />Hepatobiliary<br />Disorders<br />Hepatic<br />enzyme<br />increased<br />(ALT/AST,<br />alkaline<br />phosphatase,<br />GGT)<br />Blood bilirubin<br />Increased<br />Jaundice and severe liver injury, including cases with fatal acute liver failure, primarily in patients with severe underlying diseases<br />(see section 4.4) Hepatitis<br />Skin and<br />subcutaneous<br />tissue disordersb<br />Rash<br />Pruritus<br />Urticaria<br />Hyperhidrosis<br />Toxic epidermal necrolysis<br />Stevens-Johnson syndrome<br />Erythema multiforme<br />Photosensitivity reaction (see<br />section 4.4) Leukocytoclastic vasculitis Stomatitis<br />Musculoskeletal<br />and connective<br />tissue disorders<br />Arthralgia<br />Myalgia<br />Tendon disorder (see<br />sections 4.3 and 4.4)<br />including tendinitis (e.g.<br />Achilles tendon)<br />Muscular weakness which may be of<br />Rhabdomyolysis Tendon rupture (e.g. Achilles<br />tendon) (see sections 4.3 and 4.4) Ligament rupture<br />Muscle rupture Arthritis</p><p>importance in patients with myasthenia gravis (see section 4.4)<br />Renal and urinary<br />Disorders<br />Blood creatinine<br />Increased<br />Renal failure acute (e.g.<br />due to interstitial nephritis)<br />General disorders<br />and administration<br />site conditions<br />Applies to iv<br />form only:<br />Infusion site<br />reaction (pain,<br />reddening)<br />Asthenia<br />Pyrexia<br />Pain (including pain in back,<br />chest, and extremities)<br />a Anaphylactic and anaphylactoid reactions may sometimes occur even after the first dose<br />bMucocutaneous reactions may sometimes occur even after the first dose<br />Other undesirable effects which have been associated with fluoroquinolone administration include:<br />&bull; attacks of porphyria in patients with porphyria.</p><p>Reporting of suspected adverse reactions<br />Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions to<br />Reporting to National regulatory authority:<br />To report any side effects:<br />Saudi Arabia<br />The National Pharmacovigilance and Drug Safety Centre (NPC):<br />Fax: +966-11-205-7662<br />Call NPC at +966-11-2038222, Ext 2317-2356-2340<br />Reporting hotline: 19999<br />E-mail: npc.drug@sfda.gov.sa<br />Website: www.sfda.gov.sa/npc</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>According to toxicity studies in animals or clinical pharmacology studies performed with supra-therapeutic doses, the most important signs to be expected following acute overdose of Levanix tablets are central nervous system symptoms such as confusion, dizziness, impairment of&nbsp;consciousness, and convulsive seizures, increases in QT interval as well as gastro-intestinal reactions such as nausea and mucosal erosions.<br />CNS effects including confusional state, convulsion, hallucination, and tremor have been observed in post marketing experience.<br />In the event of overdose, symptomatic treatment should be implemented. ECG monitoring should be undertaken, because of the possibility of QT interval prolongation. Antacids may be used for protection of gastric mucosa. Haemodialysis, including peritoneal dialysis and CAPD, are not effective in removing levofloxacin from the body. No specific antidote exists</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>5.1 Pharmacodynamic properties<br />Pharmacotherapeutic group: quinolone antibacterials, fluoroquinolones<br />ATC code: J01MA12<br />Levofloxacin is a synthetic antibacterial agent of the fluoroquinolone class and is the S (-) enantiomer of the racemic active substance ofloxacin.<br />Mechanism of action<br />As a fluoroquinolone antibacterial agent, levofloxacin acts on the DNA-DNA-gyrase complex and topoisomerase IV.<br />PK/PD relationship<br />The degree of the bactericidal activity of levofloxacin depends on the ratio of the maximum concentration in serum (Cmax) or the area under the curve (AUC) and the minimal inhibitory concentration (MIC).<br />Mechanism of resistance<br />Resistance to levofloxacin is acquired through a stepwise process by target site mutations in both type II topoisomerases, DNA gyrase and topoisomerase IV. Other resistance mechanisms such as permeation barriers (common in Pseudomonas aeruginosa) and efflux mechanisms may also affect susceptibility to levofloxacin.<br />Cross-resistance between levofloxacin and other fluoroquinolones is observed. Due to the&nbsp;&nbsp;mechanism of action, there is generally no cross-resistance between levofloxacin and other classes of antibacterial agents.<br />Breakpoints<br />The EUCAST recommended MIC breakpoints for levofloxacin, separating susceptible from intermediately susceptible organisms and intermediately susceptible from resistant organisms are presented in the below table for MIC testing (mg/l).<br />EUCAST clinical MIC breakpoints for levofloxacin (version 2.0, 2012-01-01):<br />Pathogen<br />Susceptible<br />Resistant<br />Enterobacteriacae<br />&le;1 mg/l<br />&gt;2 mg/l<br />Pseudomonas spp.<br />&le;1 mg/l<br />&gt;2 mg/l<br />Acinetobacter spp.<br />&le;1 mg/l<br />&gt;2 mg/l<br />Staphylococcus spp.<br />&le;1 mg/l<br />&gt;2 mg/l<br />S. pneumoniae 1<br />&le;2 mg/l<br />&gt;2 mg/l<br />Streptococcus A,B,C,G<br />&le;1 mg/l<br />&gt;2 mg/l<br />H. influenzae2, 3<br />&le;1 mg/l<br />&gt;1 mg/l<br />M. catarrhalis 3<br />&le;1 mg/l<br />&gt;1 mg/l<br />Non-species related breakpoints4<br />&le;1 mg/l<br />&gt;2 mg/l<br />1. The breakpoints for levofloxacin relate to high dose therapy.<br />2. Low-level fluoroquinolone resistance (ciprofloxacin MIC&#39;s of 0.12-0.5 mg/l) may occur but there is no evidence that this resistance is of clinical importance in respiratory tract infections with H. influenzae.<br />3. Strains with MIC values above the susceptible breakpoint are very rare or not yet reported. The identification and antimicrobial susceptibility tests on any such isolate must be repeated and if the result is confirmed the isolate must be sent to a reference laboratory. Until there is evidence regarding clinical response for confirmed isolates with MIC above the current resistant breakpoint they should be reported resistant.<br />4. Breakpoints apply to an oral dose of 500 mg x 1 to 500 mg x 2 and an intravenous dose of 500 mg x 1 to 500 mg x 2</p><p>The prevalence of resistance may vary geographically and with time for selected species and local information on resistance is desirable, particularly when treating severe infections. As necessary, expert advice should be sought when the local prevalence of resistance is such that the utility of the agent in at least some types of infections is questionable.<br />Commonly susceptible species<br />Aerobic Gram-positive bacteria<br />Bacillus anthracis<br />Staphylococcus aureus methicillin-susceptible<br />Staphylococcus saprophyticus<br />Streptococci, group C and G<br />Streptococcus agalactiae<br />Streptococcus pneumoniae<br />Streptococcus pyogenes<br />Aerobic Gram- negative bacteria<br />Eikenella corrodens<br />Haemophilus influenzae<br />Haemophilus para-influenzae<br />Klebsiella oxytoca<br />Moraxella catarrhalis<br />Pasteurella multocida<br />Proteus vulgaris<br />Providencia rettgeri<br />Anaerobic bacteria<br />Peptostreptococcus<br />Other<br />Chlamydophila pneumoniae<br />Chlamydophila psittaci<br />Chlamydia trachomatis<br />Legionella pneumophila<br />Mycoplasma pneumoniae<br />Mycoplasma hominis<br />Ureaplasma urealyticum<br />Species for which acquired resistance may be a problem<br />Aerobic Gram-positive bacteria<br />Enterococcus faecalis<br />Staphylococcus aureus methicillin-resistant#<br />Coagulase negative Staphylococcus spp</p><p>Aerobic Gram- negative bacteria<br />Acinetobacter baumannii<br />Citrobacter freundii<br />Enterobacter aerogenes<br />Enterobacter cloacae<br />Escherichia coli<br />Klebsiella pneumoniae<br />Morganella morganii<br />Proteus mirabilis<br />Providencia stuartii<br />Pseudomonas aeruginosa<br />Serratia marcescens<br />Anaerobic bacteria<br />Bacteroides fragilis<br />Inherently Resistant Strains<br />Aerobic Gram-positive bacteria<br />Enterococcus faecium<br /># Methicillin-resistant S. aureus are very likely to possess co-resistance to fluoroquinolones, including levofloxacin.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Absorption<br />Orally administered levofloxacin is rapidly and almost completely absorbed with peak plasma concentrations being obtained within 1 - 2 h. The absolute bioavailability is 99 - 100 %.<br />Food has little effect on the absorption of levofloxacin.<br />Steady state conditions are reached within 48 hours following a 500 mg once or twice daily dosage regimen.<br />Distribution<br />Approximately 30 - 40 % of levofloxacin is bound to serum protein.<br />The mean volume of distribution of levofloxacin is approximately 100 l after single and repeated 500 mg doses, indicating widespread distribution into body tissues.</p><p>Penetration into tissues and body fluids:<br />Levofloxacin has been shown to penetrate into bronchial mucosa, epithelial lining fluid, alveolar macrophages, lung tissue, skin (blister fluid), prostatic tissue and urine. However, levofloxacin has poor penetration into cerebro-spinal fluid.<br />Biotransformation<br />Levofloxacin is metabolised to a very small extent, the metabolites being desmethyl-levofloxacin and levofloxacin N-oxide. These metabolites account for &lt;5 % of the dose and are excreted in urine. Levofloxacin is stereochemically stable and does not undergo chiral inversion.<br />Elimination<br />Following oral and intravenous administration of levofloxacin, it is eliminated relatively slowly from the plasma (t&frac12; : 6 - 8 h). Excretion is primarily by the renal route (&gt;85 % of the administered dose).<br />The mean apparent total body clearance of levofloxacin following a 500 mg single dose was 175 +/-29.2 ml/min.<br />There are no major differences in the pharmacokinetics of levofloxacin following intravenous and oral administration, suggesting that the oral and intravenous routes are interchangeable.<br />Linearity<br />Levofloxacin obeys linear pharmacokinetics over a range of 50 to 1000 mg.<br />Special populations<br />Subjects with renal insufficiency<br />The pharmacokinetics of levofloxacin are affected by renal impairment. With decreasing renal function renal elimination and clearance are decreased, and elimination half-lives increased as shown in the table below:<br />Pharmacokinetics in renal insufficiency following single oral 500 mg dose<br />Clcr [ml/min]<br />&lt; 20<br />20 - 49<br />50 - 80<br />ClR [ml/min]<br />13<br />26<br />57<br />t1/2 [h]<br />35<br />27<br />9</p><p>Elderly subjects<br />There are no significant differences in levofloxacin pharmacokinetics between young and elderly subjects, except those associated with differences in creatinine clearance.<br />Gender differences<br />Separate analysis for male and female subjects showed small to marginal gender differences in levofloxacin pharmacokinetics. There is no evidence that these gender differences are of clinical relevance.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Non-clinical data reveal no special hazard for humans based on conventional studies of single dose toxicity, repeated dose toxicity, carcinogenic potential and toxicity to reproduction and development.<br />Levofloxacin caused no impairment of fertility or reproductive performance in rats and its only effect on fetuses was delayed maturation as a result of maternal toxicity.<br />Levofloxacin did not induce gene mutations in bacterial or mammalian cells but did induce chromosome aberrations in Chinese hamster lung cells in vitro. These effects can be attributed to inhibition of topoisomerase II. In vivo tests (micronucleus, sister chromatid exchange, unscheduled DNA synthesis, dominant lethal tests) did not show any genotoxic potential.<br />Studies in the mouse showed levofloxacin to have phototoxic activity only at very high doses. Levofloxacin did not show any genotoxic potential in a photomutagenicity assay, and it reduced tumour development in a photocarcinogenity study.<br />In common with other fluoroquinolones, levofloxacin showed effects on cartilage (blistering and cavities) in rats and dogs. These findings were more marked in young animals.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>6.1. List of excipients:<br />&bull; Microcrystalline Cellulose BP (Grade 101)<br />&bull; Maize Starch Ph.Eur.<br />&bull; Crospovidone BP (Type A)<br />&bull; Sodium Stearyl Fumarate USP</p><p>&bull; Titanium Dioxide BP<br />&bull; Hypromellose BP/Ph.Eur. (E6 LV)<br />&bull; Ferric Oxide Yellow USPNF<br />&bull; Ferric Oxide Red USPNF<br />&bull; Purified Water USP/BP</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>None known</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                36 months
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30&deg;C</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The tablets are packed in Alu/Alu blisters and placed in a printed carton along with a pack insert.<br />Pack size: 5&rsquo;s &amp; 7&rsquo;s.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>None known</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                7. Manufacturer:
Neopharma, Abu Dhabi, UAE
Plot No. A1 89-95,
Industrial City of Abu Dhabi (ICAD),
Mussafah, Abu Dhabi, UAE
8. Marketing Authorization Holder:
Neopharma, Abu Dhabi, UAE
Plot No. A1 89-95,
Industrial City of Abu Dhabi (ICAD),
Mussafah, Abu Dhabi, UAE
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                January 2019
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>